Kiora Pharmaceuticals Inc. [NASDAQ: KPRX] jumped around 0.04 points on Tuesday, while shares priced at $0.23 at the close of the session, up 21.00%. The company report on September 13, 2022 that Kiora Pharmaceuticals Appoints Melissa Tosca as Executive Vice President of Finance.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Salt Lake City, Utah–(Newsfile Corp. – September 13, 2022) – Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (“Kiora” or the “Company”) has appointed Melissa Tosca as Executive Vice President of Finance. Mrs. Tosca will join the executive management team and oversee finance, SEC reporting and accounting functions as well as play a role in the company’s capital markets strategy and planning.
“Melissa brings to our company more than 15 years of financial and operational experience in both clinical and commercial-stage biotech and life science companies,” said Brian M. Strem, Ph.D., President and CEO of Kiora. “This experience will be invaluable to our goals of advancing our development pipeline and supporting our next phase of growth.”.
Kiora Pharmaceuticals Inc. stock is now -84.77% down from its year-to-date (YTD) trading value. KPRX Stock saw the intraday high of $0.2838 and lowest of $0.183 per share. The company’s 52-week high price is 2.34, which means current price is +89.22% above from all time high which was touched on 01/03/22.
Compared to the average trading volume of 8.98M shares, KPRX reached a trading volume of 57672810 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Kiora Pharmaceuticals Inc. [KPRX]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for KPRX shares is $8.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on KPRX stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Average True Range (ATR) for Kiora Pharmaceuticals Inc. is set at 0.03 The Price to Book ratio for the last quarter was 0.34, with the Price to Cash per share for the same quarter was set at 0.07.
How has KPRX stock performed recently?
Kiora Pharmaceuticals Inc. [KPRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 14.95. With this latest performance, KPRX shares gained by 41.48% in over the last four-week period, additionally sinking by -64.63% over the last 6 months – not to mention a drop of -86.32% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for KPRX stock in for the last two-week period is set at 57.49, with the RSI for the last a single of trading hit 63.33, and the three-weeks RSI is set at 52.79 for Kiora Pharmaceuticals Inc. [KPRX]. The present Moving Average for the last 50 days of trading for this stock 0.2180, while it was recorded at 0.1983 for the last single week of trading, and 0.5747 for the last 200 days.
Kiora Pharmaceuticals Inc. [KPRX]: Deeper insight into the fundamentals
Return on Equity for this stock declined to -127.63, with Return on Assets sitting at -78.05.
Kiora Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.50 and a Current Ratio set at 1.50.
Insider trade positions for Kiora Pharmaceuticals Inc. [KPRX]
There are presently around $0 million, or 8.10% of KPRX stock, in the hands of institutional investors. The top three institutional holders of KPRX stocks are: GEODE CAPITAL MANAGEMENT, LLC with ownership of 547,128, which is approximately 3.278% of the company’s market cap and around 2.00% of the total institutional ownership; VANGUARD GROUP INC, holding 67,212 shares of the stock with an approximate value of $15000.0 in KPRX stocks shares; and PRICE T ROWE ASSOCIATES INC /MD/, currently with $12000.0 in KPRX stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Kiora Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 7 institutional holders increased their position in Kiora Pharmaceuticals Inc. [NASDAQ:KPRX] by around 109,719 shares. Additionally, 7 investors decreased positions by around 105,003 shares, while 4 investors held positions by with 621,438 shares. The mentioned changes placed institutional holdings at 836,160 shares, according to the latest SEC report filing. KPRX stock had 2 new institutional investments in for a total of 61,440 shares, while 4 institutional investors sold positions of 43,405 shares during the same period.